Table 3.

Comparison between groups according to treatment response.

Variables	CR/PR group (n = 12)	SD group (n = 8)	p value
Age (year)	1.8 (0.2–18.8)	5.1 (0.1–18.8)	0.285
Sex			1.000
Male	8 (66.7%)	6 (75.0%)
Female	4 (33.3%)	2 (25.0%)
Diagnosis			0.015
Vascular tumor	7 (58.3%)	0 (0.0%)
VM or LM	5 (41.7%)	8 (100%)
Location			0.083
Head or Neck	6 (50.0%)	3 (37.5%)
Extremities	3 (25.0%)	0 (0.0%)
Trunk	3 (25.0%)	2 (25.0%)
Extensive lesions	0 (0.0%)	3 (37.5%)
Measurable lesions (yes)	10 (83.3%)	1 (12.5%)	0.005
Duration of sirolimus treatment (year)	2.2 (1.0–4.3)	1.1 (0.6–3.6)	0.399
Mean serum trough level of sirolimus (ng/mL)	7.9 (3.6–10.3)	7.0 (6.0–14.0)	0.492

CR, Complete Response; LM, Lymphatic Malformation; PR, Partial Response; SD, Stable Disease; VM, Venous Malformation.